Skip to content

Study · In vitro (cells) · rat · 1989

4 results

Interaction of thymic peptide thymosin alpha 1 with VIP receptors in rat intestinal epithelial cells: comparison with PHI and secretin.

Calvo JR, Guerrero JM, Goberna R

General pharmacology1 Jan 1989Cited by 8 (Europe PMC)

PMID2546855 (opens in a new tab)DOI10.1016/0306-3623(89)90203-6 (opens in a new tab)PepBankPUB-02546855
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In rat intestinal epithelial cells, thymosin alpha‑1 inhibited the specific binding of 125I-labelled VIP.

    In plain wordsIn rat gut cells, thymosin alpha‑1 reduced the binding of VIP to its receptors.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseInhibition of 125I-VIP specific binding
    Study

    ratn: not reported in source

    intestinal epithelial cells
    Comparator
    VIP
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    10(-10)-10(-7) MAs given in this study (rat).

    Source sentences

    Summary
    Thymic peptide thymosin alpha 1 (10(-10)-10(-7) M) is shown to inhibit the specific binding of 125I-labelled VIP.
  2. 02LabIn vitro (cells)Activity measurement

    In rat intestinal epithelial cells, thymosin alpha‑1 was 1500 times less potent than VIP at inhibiting 125I-labelled VIP binding.

    In plain wordsIn rat gut cells, thymosin alpha‑1 was far weaker than VIP at blocking VIP binding.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicablePotency at inhibiting 125I-VIP binding relative to VIP
    Study

    ratn: not reported in source

    intestinal epithelial cells
    Comparator
    VIP
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    10(-10)-10(-7) MAs given in this study (rat).

    Measurements

    Potency relative to VIP
    1500 times less potent
    inhibition of 125I-VIP binding

    Source sentences

    Summary
    Thymosin alpha 1 was 1500 times less potent than VIP at inhibiting 125I-labelled VIP binding.
  3. 03LabIn vitro (cells)Activity measurement

    In rat intestinal epithelial cells, thymosin alpha‑1 only weakly stimulated cyclic AMP production.

    In plain wordsIn rat gut cells, thymosin alpha‑1 only weakly raised cyclic AMP production.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCyclic AMP production
    Study

    ratn: not reported in source

    intestinal epithelial cells
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    10(-10)-10(-7) MAs given in this study (rat).

    Source sentences

    Summary
    Thymosin alpha 1 (10(-10)-10(-7) M) was weak in stimulating cyclic AMP production.
  4. 04LabIn vitro (cells)Activity measurement

    In rat intestinal epithelial cells, affinity for VIP receptors ranked VIP, then PHI, then secretin, then thymosin alpha‑1.

    In plain wordsIn rat gut cells, thymosin alpha‑1 had the weakest affinity for VIP receptors of the four peptides compared.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableOrder of affinity for VIP receptors
    Study

    ratn: not reported in source

    intestinal epithelial cells
    Comparator
    VIP, PHI, secretin
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    10(-10)-10(-7) MAs given in this study (rat).

    Source sentences

    Summary
    The order of affinity of different peptides is VIP greater than PHI greater than secretin greater than thymosin alpha 1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.